Checkpoint Therapeutics Initiates Registrational Development Programs for Anti-PD-L1 Antibody CK-301
NEW YORK, Jan. 7 (Korea Bizwire) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that the ongoing multi-center clinical trial of CK-301 has been expanded to enroll patients in three cohorts intended to [...]